Published in PLoS Med on March 07, 2006
Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol (2011) 3.68
Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol (2014) 2.74
MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med (2012) 2.20
MMPs as therapeutic targets--still a viable option? Semin Cell Dev Biol (2007) 1.78
The role of osteopontin in the development of albuminuria. J Am Soc Nephrol (2008) 1.33
Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages. Proc Natl Acad Sci U S A (2010) 1.33
Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis. Am J Physiol Gastrointest Liver Physiol (2009) 1.31
Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. Endocrine (2008) 1.30
Investigating mechanisms of chronic kidney disease in mouse models. Pediatr Nephrol (2011) 1.26
Role for macrophage metalloelastase in glomerular basement membrane damage associated with alport syndrome. Am J Pathol (2006) 1.20
Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatr Nephrol (2012) 1.17
Alport syndrome--insights from basic and clinical research. Nat Rev Nephrol (2012) 1.14
Matrix metalloproteinases in kidney homeostasis and diseases. Am J Physiol Renal Physiol (2012) 1.11
Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome. J Clin Invest (2010) 1.09
Biomechanical strain causes maladaptive gene regulation, contributing to Alport glomerular disease. Kidney Int (2009) 1.03
Mechanisms and consequences of TGF-ß overexpression by podocytes in progressive podocyte disease. Cell Tissue Res (2011) 0.98
Injection of amniotic fluid stem cells delays progression of renal fibrosis. J Am Soc Nephrol (2012) 0.98
Alport syndrome: its effects on the glomerular filtration barrier and implications for future treatment. J Physiol (2014) 0.97
MMP-9 gene deletion mitigates microvascular loss in a model of ischemic acute kidney injury. Am J Physiol Renal Physiol (2011) 0.97
Integrin alpha1beta1 regulates matrix metalloproteinases via P38 mitogen-activated protein kinase in mesangial cells: implications for Alport syndrome. Am J Pathol (2008) 0.97
Tissues use resident dendritic cells and macrophages to maintain homeostasis and to regain homeostasis upon tissue injury: the immunoregulatory role of changing tissue environments. Mediators Inflamm (2012) 0.96
α1β1 integrin/Rac1-dependent mesangial invasion of glomerular capillaries in Alport syndrome. Am J Pathol (2013) 0.96
Glomerular matrix metalloproteinases and their regulators in the pathogenesis of lupus nephritis. Arthritis Res Ther (2008) 0.95
Ocular features in Alport syndrome: pathogenesis and clinical significance. Clin J Am Soc Nephrol (2015) 0.94
Feasibility of repairing glomerular basement membrane defects in Alport syndrome. J Am Soc Nephrol (2013) 0.94
Matrix metalloproteinases contribute to kidney fibrosis in chronic kidney diseases. World J Nephrol (2013) 0.91
Mild electrical stimulation and heat shock ameliorates progressive proteinuria and renal inflammation in mouse model of Alport syndrome. PLoS One (2012) 0.91
Laminin α2-mediated focal adhesion kinase activation triggers Alport glomerular pathogenesis. PLoS One (2014) 0.90
Novel actions of tissue-type plasminogen activator in chronic kidney disease. Front Biosci (2008) 0.90
A delicate balance: role of MMP-9 in brain development and pathophysiology of neurodevelopmental disorders. Front Cell Neurosci (2015) 0.90
Glomerular pathology in Alport syndrome: a molecular perspective. Pediatr Nephrol (2011) 0.88
Metalloprotease meprin beta in rat kidney: glomerular localization and differential expression in glomerulonephritis. PLoS One (2008) 0.88
MT1-MMP-mediated basement membrane remodeling modulates renal development. Exp Cell Res (2010) 0.88
A glimpse of matrix metalloproteinases in diabetic nephropathy. Curr Med Chem (2014) 0.84
Diagnosis of Alport syndrome without biopsy? Pediatr Nephrol (2006) 0.83
An update on the pathomechanisms and future therapies of Alport syndrome. Pediatr Nephrol (2012) 0.82
CD166/ALCAM mediates proinflammatory effects of S100B in delayed type hypersensitivity. J Immunol (2013) 0.80
Thrombospondin-1 deficiency causes a shift from fibroproliferative to inflammatory kidney disease and delays onset of renal failure. Am J Pathol (2014) 0.79
Upregulated expression of integrin α1 in mesangial cells and integrin α3 and vimentin in podocytes of Col4a3-null (Alport) mice. PLoS One (2012) 0.78
A maladaptive role for EP4 receptors in mouse mesangial cells. PLoS One (2014) 0.77
Searching for a treatment for Alport syndrome using mouse models. World J Nephrol (2014) 0.77
Membrane-type 4 matrix metalloproteinase (MT4-MMP) modulates water homeostasis in mice. PLoS One (2011) 0.76
Collagen IV diseases: A focus on the glomerular basement membrane in Alport syndrome. Matrix Biol (2016) 0.76
Matrix Metalloproteinase-2 Knockout and Heterozygote Mice Are Protected from Hydronephrosis and Kidney Fibrosis after Unilateral Ureteral Obstruction. PLoS One (2015) 0.76
Matrix metalloproteinases, atherosclerosis, proteinuria and kidney disease: Linkage-based approaches. Hippokratia (2013) 0.75
Role of the prostaglandin E2/E-prostanoid 2 receptor signalling pathway in TGFβ-induced mice mesangial cell damage. Biosci Rep (2014) 0.75
X-Linked Alport Dogs Demonstrate Mesangial Filopodial Invasion of the Capillary Tuft as an Early Event in Glomerular Damage. PLoS One (2016) 0.75
Metalloproteinases: a Functional Pathway for Myeloid Cells. Microbiol Spectr (2016) 0.75
Endothelin-1 mediated induction of extracellular matrix genes in strial marginal cells underlies strial pathology in Alport mice. Hear Res (2016) 0.75
COL4A4 gene study of a European population: description of new mutations causing autosomal dominant Alport syndrome. Int J Mol Epidemiol Genet (2014) 0.75
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol (2000) 13.29
MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell (1998) 9.70
BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med (2003) 7.91
Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer (2003) 6.65
Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med (2003) 4.77
A network model for the organization of type IV collagen molecules in basement membranes. Eur J Biochem (1981) 4.19
Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science (1990) 4.15
Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell (2003) 3.68
Pathophysiology of progressive nephropathies. N Engl J Med (1998) 3.61
Structure and biological activity of basement membrane proteins. Eur J Biochem (1989) 3.44
Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol (1996) 2.97
Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency. Nat Immunol (2002) 2.83
X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol (2000) 2.71
Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome. Genes Dev (1996) 2.58
Molecular and functional defects in kidneys of mice lacking collagen alpha 3(IV): implications for Alport syndrome. J Cell Biol (1996) 2.29
Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol (2003) 2.20
Identification of mutations in the alpha 3(IV) and alpha 4(IV) collagen genes in autosomal recessive Alport syndrome. Nat Genet (1994) 2.12
Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis. J Clin Invest (1997) 2.03
Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction. Arthritis Rheum (1998) 2.00
Determinants of vascular permeability in the kidney glomerulus. J Biol Chem (2002) 1.93
Integrin alpha1beta1 and transforming growth factor-beta1 play distinct roles in alport glomerular pathogenesis and serve as dual targets for metabolic therapy. Am J Pathol (2000) 1.90
HEREDITARY FAMILIAL CONGENITAL HAEMORRHAGIC NEPHRITIS. Br Med J (1927) 1.77
Gene expression fingerprints in human tubulointerstitial inflammation and fibrosis as prognostic markers of disease progression. Kidney Int (2004) 1.72
Quantitative trait loci influence renal disease progression in a mouse model of Alport syndrome. Am J Pathol (2002) 1.67
Monocytes may promote myofibroblast accumulation and apoptosis in Alport renal fibrosis. Kidney Int (2003) 1.60
Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation (2004) 1.57
Coordinate expression of matrix metalloproteinase family members in the uterus of normal, matrilysin-deficient, and stromelysin-1-deficient mice. Endocrinology (1997) 1.50
Matrix metalloproteinase 9 protects mice from anti-glomerular basement membrane nephritis through its fibrinolytic activity. J Exp Med (2001) 1.43
Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. J Med Chem (1998) 1.41
Degradation of human glomerular basement membrane by stimulated neutrophils. Activation of a metalloproteinase(s) by reactive oxygen metabolites. J Clin Invest (1987) 1.38
COL4A3/COL4A4 mutations: from familial hematuria to autosomal-dominant or recessive Alport syndrome. Kidney Int (2002) 1.35
Protein degradation following treatment with hydrogen peroxide. Am J Pathol (1984) 1.30
Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int (1997) 1.23
Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J Med Chem (1997) 1.22
Hereditary nephropathy (Alport syndrome): correlation of clinical data with glomerular basement membrane alterations. Clin Nephrol (1980) 1.20
Hypoxia-induced changes in extracellular matrix metabolism in renal cells. Exp Nephrol (1999) 1.19
Gelatinase B (MMP-9) is not essential in the normal kidney and does not influence progression of renal disease in a mouse model of Alport syndrome. Am J Pathol (2000) 1.16
Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res (1992) 1.11
Familial hematuria due to type IV collagen mutations: Alport syndrome and thin basement membrane nephropathy. Curr Opin Pediatr (2004) 1.10
Increased expression of MMP-2, MMP-9 (type IV collagenases/gelatinases), and MT1-MMP in canine X-linked Alport syndrome (XLAS). Kidney Int (2003) 1.05
The importance of tubulointerstitial damage in progressive renal disease. Nephrol Dial Transplant (2000) 0.99
Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer (1996) 0.95
Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: possible role in diabetic nephropathy. Kidney Int Suppl (2000) 0.95
Expression of the type IV collagenase system during mouse kidney development and tubule segmentation. J Am Soc Nephrol (2001) 0.94
Relaxin-1-deficient mice develop an age-related progression of renal fibrosis. Kidney Int (2004) 0.94
Assembly of basement membranes. Ann N Y Acad Sci (1990) 0.92
Effects of pentoxifylline, pentifylline and gamma-interferon on proliferation, differentiation, and matrix synthesis of human renal fibroblasts. Nephrol Dial Transplant (2000) 0.91
Reactive oxygen species expose cryptic epitopes associated with autoimmune goodpasture syndrome. J Biol Chem (2000) 0.91
Matrix metalloproteinase 2 (MMP2) and MMP9 are produced by kidney collecting duct principal cells but are differentially regulated by SV40 large-T, arginine vasopressin, and epidermal growth factor. J Biol Chem (1999) 0.90
The pathology of the kidney in the Alport syndrome. Birth Defects Orig Artic Ser (1974) 0.85
Actual invasive potential of human hepatocellular carcinoma revealed by in situ gelatin zymography. Clin Cancer Res (2001) 0.81
Immunohistologic findings in Alport syndrome. Contrib Nephrol (1996) 0.80
A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid. Cancer Chemother Pharmacol (2004) 0.77
Inflammation and cancer. Nature (2002) 53.78
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
Matrix metalloproteinases: regulators of the tumor microenvironment. Cell (2010) 12.90
Lifeact: a versatile marker to visualize F-actin. Nat Methods (2008) 12.23
The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol (2006) 11.16
Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol (2007) 10.17
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med (2007) 9.51
Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell (2002) 9.36
HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell (2008) 8.01
BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med (2003) 7.91
Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature (2005) 7.24
Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med (2009) 6.72
The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol (2012) 6.07
Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol (2008) 5.83
beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell (2002) 5.56
TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet (2005) 5.53
Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem (2007) 5.37
Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med (2006) 5.22
Stromal effects on mammary gland development and breast cancer. Science (2002) 5.22
GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell (2006) 4.98
Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med (2010) 4.88
Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci U S A (2003) 4.69
Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest (2004) 4.65
PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol (2005) 4.57
Origin and function of myofibroblasts in kidney fibrosis. Nat Med (2013) 4.55
Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther (2006) 4.20
Collective epithelial migration and cell rearrangements drive mammary branching morphogenesis. Dev Cell (2008) 4.18
Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol (2004) 4.16
Modification of kidney barrier function by the urokinase receptor. Nat Med (2007) 4.01
Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med (2002) 4.00
Tumors as organs: complex tissues that interface with the entire organism. Dev Cell (2010) 3.98
Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res (2007) 3.86
Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell (2003) 3.68
eRNAs are required for p53-dependent enhancer activity and gene transcription. Mol Cell (2012) 3.63
Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med (2010) 3.60
Altered endochondral bone development in matrix metalloproteinase 13-deficient mice. Development (2004) 3.45
GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell (2008) 3.44
Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol (2011) 3.36
Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem (2003) 3.36
The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med (Berl) (2004) 3.32
Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell (2012) 3.19
Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int (2002) 3.16
Regulation of mammary gland branching morphogenesis by the extracellular matrix and its remodeling enzymes. Breast Cancer Res (2003) 3.13
Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest (2012) 3.09
Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc Natl Acad Sci U S A (2006) 3.03
Endogenous inhibitors of angiogenesis. Cancer Res (2005) 2.88
Loss of β1-integrin from urothelium results in overactive bladder and incontinence in mice: a mechanosensory rather than structural phenotype. FASEB J (2013) 2.86
Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J Biol Chem (2002) 2.86
Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency. Nat Immunol (2002) 2.83
Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin. Development (2005) 2.73
Tube or not tube: remodeling epithelial tissues by branching morphogenesis. Dev Cell (2003) 2.70
Site-specific inductive and inhibitory activities of MMP-2 and MMP-3 orchestrate mammary gland branching morphogenesis. J Cell Biol (2003) 2.68
Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem (2007) 2.67
Cancer without disease. Nature (2004) 2.65
Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell (2012) 2.61
Hormonal and local control of mammary branching morphogenesis. Differentiation (2006) 2.60
Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nat Med (2013) 2.55
Biomolecular characterization and protein sequences of the Campanian hadrosaur B. canadensis. Science (2009) 2.48
Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat Med (2012) 2.44
Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res (2007) 2.41
Altered fracture repair in the absence of MMP9. Development (2003) 2.41
Cyclins E1 and E2 are required for endoreplication in placental trophoblast giant cells. EMBO J (2003) 2.34
Visualizing stromal cell dynamics in different tumor microenvironments by spinning disk confocal microscopy. Dis Model Mech (2008) 2.34
Structure and function of basement membranes. Exp Biol Med (Maywood) (2007) 2.29
Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci U S A (2003) 2.28
Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science (2002) 2.28
Lentiviral transduction of mammary stem cells for analysis of gene function during development and cancer. Cell Stem Cell (2008) 2.24
TGF-β1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis. J Am Soc Nephrol (2012) 2.24
Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. J Neurosci (2002) 2.21
Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci U S A (2011) 2.21
ECM microenvironment regulates collective migration and local dissemination in normal and malignant mammary epithelium. Proc Natl Acad Sci U S A (2012) 2.20
Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol (2003) 2.20
The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol (2010) 2.18
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell (2011) 2.17
Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted. Physiol Rev (2007) 2.14
Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J Biol Chem (2004) 2.13
Cell-polarity dynamics controls the mechanism of lumen formation in epithelial morphogenesis. Curr Biol (2008) 2.13
Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl) (2013) 2.12
Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature (2008) 2.09
HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1. BMC Biochem (2006) 2.09
The role of the microenvironment in mammary gland development and cancer. Cold Spring Harb Perspect Biol (2010) 2.03
Candidate regulators of mammary branching morphogenesis identified by genome-wide transcript analysis. Dev Dyn (2006) 2.03
GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nat Cell Biol (2013) 2.03
BMP-7 functions as a novel hormone to facilitate liver regeneration. FASEB J (2006) 2.02
Patterning mechanisms of branched organs. Science (2008) 2.00
The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G protein-coupled receptors. J Cell Biol (2002) 1.99
The MAPK(ERK-1,2) pathway integrates distinct and antagonistic signals from TGFalpha and FGF7 in morphogenesis of mouse mammary epithelium. Dev Biol (2007) 1.98
Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer. Neoplasia (2005) 1.98
Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology (2003) 1.97
Genetic mosaic analysis reveals FGF receptor 2 function in terminal end buds during mammary gland branching morphogenesis. Dev Biol (2008) 1.97
Matrix remodeling during endochondral ossification. Trends Cell Biol (2004) 1.97
Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell (2012) 1.95
Dynamic, long-term in vivo imaging of tumor-stroma interactions in mouse models of breast cancer using spinning-disk confocal microscopy. Cold Spring Harb Protoc (2011) 1.95
Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes (2007) 1.94
Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilization. J Exp Med (2005) 1.93
Determinants of vascular permeability in the kidney glomerulus. J Biol Chem (2002) 1.93